Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As subcutaneous monotherapy for adults with metastatic MSI-high or mismatch repair-deficient colorectal cancer after progression following fluoropyrimidine, oxaliplatin, and irinotecan.
LAMPGEN ANALYSIS
Why it matters
The supplement fulfilled postmarketing requirements and converted the existing subcutaneous post-chemotherapy use to traditional approval.
What research teams should watch
Keep this post-chemotherapy pathway distinct from the same-day use after intravenous dual immunotherapy.
PRIMARY RECORDS